Literature DB >> 10364301

The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes.

E Konishi1, M Yamaoka, I Kurane, K Takada, P W Mason.   

Abstract

For Japanese encephalitis (JE), we previously reported that recombinant vaccine-induced protection from disease does not prevent challenge virus replication in mice. Moreover, DNA vaccines for JE can provide protection from high challenge doses in the absence of detectable prechallenge neutralizing antibodies. In the present study, we evaluated the role of postchallenge immune responses in determining the outcome of JE virus infection, using mice immunized with a plasmid, pcDNA3JEME, encoding the JE virus premembrane (prM) and envelope (E) coding regions. In the first experiment, 10 mice were vaccinated once (five animals) or twice (remainder) with 100 micrograms of pcDNA3JEME. All of these mice showed low (6 of 10) or undetectable (4 of 10) levels of neutralizing antibodies. Interestingly, eight of these animals showed a rapid rise in neutralizing antibody following challenge with 10,000 50% lethal doses of JE virus and survived for 21 days, whereas only one of the two remaining animals survived. No unimmunized animals exhibited a rise of neutralizing antibody or survived challenge. Levels of JE virus-specific immunoglobulin M class antibodies were elevated following challenge in half of the unimmunized mice and in the single pcDNA3JEME-immunized mouse that died. In the second experiment, JE virus-specific primary cytotoxic T-lymphocyte (CTL) activity was detected in BALB/c mice immunized once with 100 micrograms of pcDNA3JEME 4 days after challenge, indicating a strong postchallenge recall of CTLs. In the third experiment, evaluation of induction of CTLs and antibody activity by plasmids containing portions of the prM/E cassette demonstrated that induction of CTL responses alone were not sufficient to prevent death. Finally, we showed that antibody obtained from pcDNA3JEME-immunized mice 4 days following challenge could partially protect recipient mice from lethal challenge. Taken together, these results indicate that neutralizing antibody produced following challenge provides the critical protective component in pcDNA3JEME-vaccinated mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364301      PMCID: PMC112610     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein.

Authors:  T R Kreil; E Maier; S Fraiss; M M Eibl
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

2.  Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes.

Authors:  E Konishi; M Yamaoka; I Kurane; P W Mason
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Partial nucleotide sequence of the Japanese encephalitis virus genome.

Authors:  P C McAda; P W Mason; C S Schmaljohn; J M Dalrymple; T L Mason; M J Fournier
Journal:  Virology       Date:  1987-06       Impact factor: 3.616

4.  Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4.

Authors:  I Kurane; L Zeng; M A Brinton; F A Ennis
Journal:  Virology       Date:  1998-01-20       Impact factor: 3.616

5.  Recognition of dengue virus NS1-NS2a proteins by human CD4+ cytotoxic T lymphocyte clones.

Authors:  S Green; I Kurane; S Pincus; E Paoletti; F A Ennis
Journal:  Virology       Date:  1997-08-04       Impact factor: 3.616

6.  DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice.

Authors:  Y L Lin; L K Chen; C L Liao; C T Yeh; S H Ma; J L Chen; Y L Huang; S S Chen; H Y Chiang
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Monoclonal antibodies multireactive with parasite antigens produced by hybridomas generated from naive mice.

Authors:  E Konishi
Journal:  Parasitology       Date:  1997-10       Impact factor: 3.234

8.  Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes.

Authors:  M Kozak
Journal:  Cell       Date:  1986-01-31       Impact factor: 41.582

9.  Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses.

Authors:  K R Porter; T J Kochel; S J Wu; K Raviprakash; I Phillips; C G Hayes
Journal:  Arch Virol       Date:  1998       Impact factor: 2.574

10.  Host defence mechanisms against Japanese encephalitis virus infection in mice.

Authors:  A Mathur; K L Arora; U C Chaturvedi
Journal:  J Gen Virol       Date:  1983-04       Impact factor: 3.891

View more
  29 in total

1.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

2.  Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.

Authors:  T P Monath; I Levenbook; K Soike; Z X Zhang; M Ratterree; K Draper; A D Barrett; R Nichols; R Weltzin; J Arroyo; F Guirakhoo
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes.

Authors:  T Liu; T J Chambers
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses.

Authors:  C H Pan; H W Chen; H W Huang; M H Tao
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice.

Authors:  Brian Nickols; Irina Tretyakova; Alexander Tibbens; Elena Klyushnenkova; Peter Pushko
Journal:  Virology       Date:  2017-09-19       Impact factor: 3.616

6.  JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody.

Authors:  Maximilian Larena; Natalie A Prow; Roy A Hall; Nikolai Petrovsky; Mario Lobigs
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

7.  Utilization of complement-dependent cytotoxicity to measure low levels of antibodies: application to nonstructural protein 1 in a model of Japanese encephalitis virus.

Authors:  Eiji Konishi; Yoko Kitai; Takashi Kondo
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

8.  A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.

Authors:  Xiao-Feng Li; Yong-Qiang Deng; Hui-Qiang Yang; Hui Zhao; Tao Jiang; Xue-Dong Yu; Shi-Hua Li; Qing Ye; Shun-Ya Zhu; Hong-Jiang Wang; Yu Zhang; Jie Ma; Yong-Xin Yu; Zhong-Yu Liu; Yu-Hua Li; E-De Qin; Pei-Yong Shi; Cheng-Feng Qin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

Review 9.  Japanese encephalitis and vaccines: past and future prospects.

Authors:  Maria Paulke-Korinek; Herwig Kollaritsch
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

10.  JE Nakayama/JE SA14-14-2 virus structural region intertypic viruses: biological properties in the mouse model of neuroinvasive disease.

Authors:  Thomas J Chambers; Deborah A Droll; Xiaoshan Jiang; William S M Wold; Janice A Nickells
Journal:  Virology       Date:  2007-05-22       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.